Publication | Closed Access

Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity

NanomedicineCancer ImmunosurveillanceMedicineImmunologyTumor ImmunityTherapeutic VaccineTumor TargetingImmunotherapyToll-like Receptor 4Cell BiologyTumor MicroenvironmentCancer-associated Antigen